Moderated Poster

Poster, Podium & Video Sessions

MP16-14: Clinical implication of metastasectomy in metachronous metastatic renal cell carcinoma in the era of targeted therapy

Friday, May 12
1:00 PM - 3:00 PM
Location: BCEC: Room 253AB

Presentation Authors: Jong Won Kim*, Jongsoo Lee, Jae Yong Jeong, Sung Ku Kang, Jang Hee Han, Seung Hwan Lee, Won Sik Ham, Koon Ho Rha, Young Deuk Choi, Sung Joon Hong, Young Eun Yoon, Woong Kyu Han, Seoul, Korea, Republic of

Introduction: To assess the clinical implication of complete and incomplete metastasectomy in the patients having metachronous metastatic RCC (mRCC).

Methods: We retrospectively reviewed metachronous mRCC treated at our institute between January 2005 and December 2015. Metachronous mRCC was defined as those diagnosed of metastatic disease >3month after initial nephrectomy. Patients were classified into three groups; A. targeted therapy for metachronouc mRCC without additional surgical treatment. B. complete metastasectomy and adjuvant targeted therapy. C. incomplete metastasectomy and adjuvant targeted therapy. Cox proportional hazard regression analysis was performed to determine if complete and incomplete metastasectomy prolongs overall survival (OS) for the metachronous mRCC.

Results: Total of 101 patients were enrolled and followed up for 41.9 months in this study. 22 patients (21.8%) underwent complete metastasectomy, while 17 patients (16.8%) underwent incomplete metastasectomy. Most commonly performed metastasectomy was lung wedge resection (n=14, 13.9%), followed by bone excision (n=9, 8.9%), and local recur resection (n=6, 5.9%). Overall, incomplete metastasectomy and complete metastasectomy prolonged OS (HR 0.608, 0.318, p=0.042, respectively). Complete and incomplete lung wedge resection both prolonged overall survival significantly (p<0.05). Metastasectomy for bone and retroperitoneum recurred mass both did not show survival benefit (p=0.590 and 0.133, respectively). For the other metastasis, we labeled them as soft tissue metastasis, and soft tissue metastasectomy prolonged OS (p=0.036). Incomplete metastasectomy for soft tissue prolonged OS (p=0.016)

Conclusions: Metastasectomy could prolong OS in metachronous mRCC. Except for metastasectomy for bone and retroperitoneum recurred mass, incomplete metastasectomy also could play a role as OS prolongation.

Source Of Funding: none

Send Email for Jong Won Kim


Assets

MP16-14: Clinical implication of metastasectomy in metachronous metastatic renal cell carcinoma in the era of targeted therapy



Attendees who have favorited this

Send Email for Clinical implication of metastasectomy in metachronous metastatic renal cell carcinoma in the era of targeted therapy